Oct 11 (Reuters) - The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday.

(Reporting by Sruthi Narasimha Chari and Christy Santhosh in Bengaluru; Editing by Vijay Kishore)

((SruthiNarasimha.Chari@thomsonreuters.com))